Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of topical immune response modifiers in skin cancer.

Literature DB >> 16978032

The role of topical immune response modifiers in skin cancer.

Courtney Woodmansee¹, Jessica Pillow, Robert B Skinner.

Abstract

Topical immune response modifiers include imiquimod and resiquimod. The mechanism of action of immune response modifiers is complex and not completely understood. It involves the stimulation of innate and cell-mediated immune responses through Toll-like receptor-mediated induction of cytokines. Imiquimod is approved for the treatment of actinic keratoses, superficial basal cell carcinomas and warts; it has also been documented to successfully treat other forms of skin cancer such as squamous cell carcinoma in situ, melanoma and extramammary Paget's disease.

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16978032 DOI： 10.2165/00003495-200666130-00001

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

32 in total

1. Topical 5% imiquimod for the therapy of actinic cheilitis.

Authors: Kathleen J Smith; Margeruite Germain; Josef Yeager; Henry Skelton
Journal: J Am Acad Dermatol Date: 2002-10 Impact factor: 11.527

Review 2. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports.

Authors: Jennifer C Zampogna; Franklin P Flowers; William I Roth; Ashraf M Hassenein
Journal: J Am Acad Dermatol Date: 2002-10 Impact factor: 11.527

3. Treatment of lentigo maligna with topical imiquimod.

Authors: M F Naylor; N Crowson; R Kuwahara; K Teague; C Garcia; C Mackinnis; R Haque; C Odom; C Jankey; R L Cornelison
Journal: Br J Dermatol Date: 2003-11 Impact factor: 9.302

4. Imiquimod 5% cream in the treatment of Bowen's disease.

Authors: A Mackenzie-Wood; S Kossard; J de Launey; B Wilkinson; M L Owens
Journal: J Am Acad Dermatol Date: 2001-03 Impact factor: 11.527

5. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.

Authors: Ingrid H Wolf; Lorenzo Cerroni; Kazuo Kodama; Helmut Kerl
Journal: Arch Dermatol Date: 2005-04

Review 6. Immunotherapy of basal cell carcinoma: evolving approaches.

Authors: Anthony A Gaspari; Daniel N Sauder
Journal: Dermatol Surg Date: 2003-10 Impact factor: 3.398

Review 7. Topical immunomodulation in dermatology: potential of toll-like receptor agonists.

Authors: Ulrich R Hengge; Thomas Ruzicka
Journal: Dermatol Surg Date: 2004-08 Impact factor: 3.398

8. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.

Authors: Michael P Schön; B Gregor Wienrich; Claudia Drewniok; Anne B Bong; Jürgen Eberle; Christoph C Geilen; Harald Gollnick; Margarete Schön
Journal: J Invest Dermatol Date: 2004-05 Impact factor: 8.551

9. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.

Authors: Daniel N Sauder; Michael H Smith; Therese Senta-McMillian; Inmaculada Soria; Tze-Chiang Meng
Journal: Antimicrob Agents Chemother Date: 2003-12 Impact factor: 5.191

10. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle.

Authors: B Berman; T Sullivan; T De Araujo; M Nadji
Journal: Br J Dermatol Date: 2003-11 Impact factor: 9.302

8 in total

1. Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors: Simone Mocellin; Donato Nitti
Journal: Oncologist Date: 2011-05-31

2. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Authors: Manisha Singh; Hiep Khong; Zhimin Dai; Xue-Fei Huang; Jennifer A Wargo; Zachary A Cooper; John P Vasilakos; Patrick Hwu; Willem W Overwijk
Journal: J Immunol Date: 2014-09-24 Impact factor: 5.422

3. [Extramammary Paget disease: successful therapy with imiquimod 5% cream].

Authors: G Wagner; M Heine; M M Sachse
Journal: Hautarzt Date: 2012-01 Impact factor: 0.751

4. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.

Authors: Kristin Turza; Lynn T Dengel; Rebecca C Harris; James W Patterson; Kevin White; William W Grosh; Craig L Slingluff
Journal: J Cutan Pathol Date: 2009-07-07 Impact factor: 1.587